CA-AFFINITY
16.6.2022 13:02:11 CEST | Business Wire | Press release
Affinity — the relationship intelligence platform for dealmakers— today launched The Relationship Intelligence Benchmark Report: Unicorn Edition , which shares industry trends and analyzes over 390 unicorns in Europe and the United Kingdom with a deep dive into relationship intelligence and deal flows of the firms that invest in them.
Integrated data from the Affinity and Dealroom.co’s intelligence platforms found Europe has a unicorn growth rate more than twice that of the US and is home to 65 “unicorn cities.” These unicorn cities consist of London, Berlin, Paris, Stockholm, and Amsterdam, with more than half of all European unicorns located in the UK and Germany. Recognizing the growth internationally, U.S. investors have flocked to join and now account for 35% of all funding in Europe. This flood of investment has also increased unicorn valuations which are up by 305% in the last five years.
“The past decade has seen an exponential increase in the volume and diversity of new capital investing in startups - and is now entering turbulent economic times,” said Ray Zhou, co-CEO and co-founder at Affinity. “Our report highlights how Europe has adapted and grown, despite the effects of the pandemic, and shows how relationship intelligence plays a role in these major industry trends.”
As expected, many firms experienced a period of “bounce back” from 2020. In 2021, European unicorns raised over $45B, twice the amount raised in 2020. However, these unicorns only account for 14% of new unicorns globally. This means the competition among VC’s is significant as they try to time the right investment. Index Ventures is a single venture responsible for backing 10 European decacorns by itself. The combination of high valuations and less late-stage funding rounds requires VC’s to capitalize on their networks, warm introductions, and outreach. But as these firms and startups face uncertain economic conditions, it is important to understand the drivers for the previous success and how investors identify the next generation of high-growth startups in Europe.
Other key takeaways from the report include:
- Unicorns are roaming : Europe produced 5 times more unicorns in 2021 than in 2020.
- Germany is now a hotspot : German funding of unicorns grew over 300% in the last 5 years. Together with the UK, they have funded 2/3 of all Europe-based unicorns.
- Decacorns are on the rise : Over the past five years, this percentage of multibillion-dollar unicorns has risen by a staggering 560%. The total value of decacorns in 2021 was $777.4B; to date in 2022 is at $718.3B, guaranteeing it will exceed 2021’s numbers.
- The rebound is over : While firms saw an increase in deals, meetings and email volume in 2021, the beginning of 2022 tells a different story. In the first quarter of 2022, firms experienced 27% less meetings and deals, likely due to the inflation in Europe and predictions of an impending recession.
Read the full report here and then watch Affinity’s webinar “European Unicorn Trends: How to Make Unicorn Hunting More Predictable ,” which brings industry experts together to discuss the trends impacting dealmakers in this report as well as the role relationship intelligence plays in the evolving market landscape.
About Affinity
Affinity is a relationship intelligence platform that empowers dealmakers in relationship-driven industries to find, manage and close more deals. With the most automated relationship intelligence insights and technology, Affinity enables leaders to drive deals, free themselves from data drudgery and ensure their teams can take action with confidence, knowing the context and history of every relationship. The Affinity platform, including Affinity CRM, is used by over 2,000 relationship-driven organizations worldwide. Founded in 2014, Affinity is headquartered in San Francisco and backed by leading investors, including Menlo Ventures, Advance Venture Partners, 8VC and MassMutual Ventures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005351/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
